Trial Exclusions May Skew RA Drug Comparisons - Scorecard - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Trial Exclusions May Skew RA Drug Comparisons

Nearly 40% of registry patients would have been excluded from phase 3 randomized controlled trials, with exclusion criteria distributed unevenly across drug classes.

  • By

  • Andrea Surnit

  • June 12, 2026

  • 5 min

Share

Clinical Scorecard: Trial Exclusions May Skew RA Drug Comparisons

At a Glance

CategoryDetail
ConditionRheumatoid Arthritis
Key MechanismsBiologic or targeted synthetic disease-modifying antirheumatic drugs
Target PopulationPatients with rheumatoid arthritis initiating treatment
Care SettingRoutine care in Japan

Key Highlights

  • 40% of patients met at least 1 trial exclusion criterion.
  • Anemia and lymphopenia were the most common exclusion criteria.
  • Janus kinase inhibitors showed higher remission rates compared to tumor necrosis factor inhibitors.

Guideline-Based Recommendations

Diagnosis

  • Assess for trial exclusion criteria including prednisolone use, renal impairment, hepatic dysfunction, anemia, lymphopenia, thrombocytopenia, and low white blood cell count.

Management

    Monitoring & Follow-up

    • Monitor disease activity and treatment response using Clinical Disease Activity Index.

    Risks

    • Be aware of potential channelling bias due to differential distribution of trial exclusion criteria across drug classes.

    Patient & Prescribing Data

    Patients with rheumatoid arthritis initiating biologic or targeted synthetic DMARDs.

    Interleukin-6 inhibitors and CTLA4-Ig were more often selected among patients with anemia or organ dysfunction.

    Clinical Best Practices

      Related Resources & Content

      Original Source(s)

      Trial Exclusions May Skew RA Drug Comparisons

      • by Andrea Surnit

      • June 12, 2026

      Related Content

      Handgrip weakness is associated with motor cortex atrophy in rheumatoid arthritis: a cross-sectional study with a hand exercise intervention

      When Bad Data Enters the Drug Pipeline

      Federal prosecutors allege that a Florida physician and research staff fabricated clinical trial records that were submitted into database systems used to evaluate investigational drugs.

      Homocitrullinated Peptides Drive Pro-Inflammatory T Cell Responses in a Humanized Mouse Model of Rheumatoid Arthritis